Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. A replay of the webcast will be available in the Investors section of the company’s website following the event.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. This approval marks a significant milestone for patients who have had limited options for managing this chronic pain condition.
Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. These trials could expand the utility of TONMYA beyond fibromyalgia, addressing other CNS disorders with significant unmet needs.
In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease characterized by hyperphagia and metabolic complications. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs target large patient populations and address critical gaps in current treatment options.
For investors, the upcoming earnings call will provide updates on the commercial launch of TONMYA, progress in clinical trials, and financial performance. The company’s diversified pipeline, spanning CNS and immunology, positions it to potentially address multiple high-need areas. However, it is important to note that Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
To view the full press release, visit https://ibn.fm/A9CfR. For the latest news and updates relating to TNXP, check the company’s newsroom at https://ibn.fm/TNXP.
